Change of Director's Interest Notice x 4
Released
Released
Announcement PDF
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
becomes ASX's property and may be made public.
Introduced 30/09/01
Amended 01/01/11
Name of entity
Alterity Therapeutics Limited
ABN
37 080 699 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for
the purposes of section 205G of the Corporations Act.
Name of director
Brian Meltzer
Date of last notice
24 April 2025
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
(1) Direct
(2) Indirect - BT PORTFOLIO SERVICES
Nature of indirect interest
(including registered holder)
(1) N/A
(2) SMSF
Date of change
(1.1) N/A
(1.2) N/A
(1.3) N/A
(1.4) N/A
(1.5) 17 September 2025
(2) N/A
No. of securities held prior to change
(1.1) 9,415,584 - FULLY PAID ORDINARY
SHARES
(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @
$0.01
(1.3) 757,576 - LISTED OPT EXP 26/02/2027 @
$0.028
(1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(1.5) 7,000,000 - UNLISTED OPT EXP 17/09/2025
@ $0.09
(2) 326,666 - FULLY PAID ORDINARY SHARES
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
Class
(1.1) FULLY PAID ORDINARY SHARES
(1.2) LISTED OPT EXP 31/08/2026 @ $0.01
(1.3) LISTED OPT EXP 26/02/2027 @ $0.028
(1.4) UNLISTED OPT EXP 30/12/2027 @ $0.01
(1.5) UNLISTED OPT EXP 17/09/2025 @ $0.09
(2) FULLY PAID ORDINARY SHARES
Number acquired
(1.1) NIL
(1.2) NIL
(1.3) NIL
(1.4) NIL
(1.5) NIL
(2) NIL
Number disposed
(1.1) NIL
(1.2) NIL
(1.3) NIL
(1.4) NIL
(1.5) (7,000,000 - UNLISTED OPT EXP 17/09/2025
@ $0.09)
(2) NIL
Value/Consideration
(1.1) N/A
(1.2) N/A
(1.3) N/A
(1.4) N/A
(1.5) NIL CONSIDERATION
(2) N/A
No. of securities held after change
(1.1) 9,415,584 - FULLY PAID ORDINARY
SHARES
(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @
$0.01
(1.3) 757,576 - LISTED OPT EXP 26/02/2027 @
$0.028
(1.4) 30,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(1.5) NIL - UNLISTED OPT EXP 17/09/2025 @
$0.09
(2) 326,666 - FULLY PAID ORDINARY SHARES
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director's Interest Notice
Nature of change
(1.1) N/A
(1.2) N/A
(1.3) N/A
(1.4) N/A
(1.5) Option Expired
(2) N/A
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities
to which interest related
prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Part 3 - +Closed period
Were the interests in the securities or
contracts
detailed above traded during a
+closed period
where prior written clearance
was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
becomes ASX's property and may be made public.
Introduced 30/09/01
Amended 01/01/11
Name of entity
Alterity Therapeutics Limited
ABN
37 080 699 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for
the purposes of section 205G of the Corporations Act.
Name of director
Geoffrey Kempler
Date of last notice
30 December 2024
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
(1) Direct
(2) Indirect - NRB Developments Pty Ltd
(3) Indirect - Sadarajak Pty Ltd
(4) Direct
(5) Indirect - Baywick Pty Ltd
(6) Indirect - Crystal Triangle Pty Ltd
Nature of indirect interest
(including registered holder)
(1) N/A
(2) Director related entity
(3) Director related entity
(4) N/A
(5) Director related entity
(6) Director related entity
Date of change
(1.1) N/A
(1.2) 17 September 2025
(2) N/A
(3) N/A
(4) N/A
(5) N/A
(6) N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
No. of securities held prior to change
(1.1) 60,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(1.2) 14,000,000 - UNLISTED OPT EXP 17/09/2025
@ $0.09
(2) 2,970,000 - FULLY PAID ORDINARY SHARES
(3) 756,000 - FULLY PAID ORDINARY SHARES
(4) 30,000 - FULLY PAID ORDINARY SHARES
(5) 14,165,000 - FULLY PAID ORDINARY SHARES
(6) 90,000 - FULLY PAID ORDINARY SHARES
Class
(1.1) UNLISTED OPT EXP 30/12/2027 @ $0.01
(1.2) UNLISTED OPT EXP 17/09/2025 @ $0.09
(2) FULLY PAID ORDINARY SHARES
(3) FULLY PAID ORDINARY SHARES
(4) FULLY PAID ORDINARY SHARES
(5) FULLY PAID ORDINARY SHARES
(6) FULLY PAID ORDINARY SHARES
Number acquired
(1.1) NIL
(1.2) NIL
(2) NIL
(3) NIL
(4) NIL
(5) NIL
(6) NIL
Number disposed
(1.1) NIL
(1.2) (14,000,000 - UNLISTED OPT EXP
17/09/2025 @ $0.09)
(2) NIL
(3) NIL
(4) NIL
(5) NIL
(6) NIL
Value/Consideration
(1.1) N/A
(1.2) NIL CONSIDERATION
(2) N/A
(3) N/A
(4) N/A
(5) N/A
(6) N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director's Interest Notice
No. of securities held after change
(1.1) 60,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(1.2) NIL - UNLISTED OPT EXP 17/09/2025 @
$0.09
(2) 2,970,000 - FULLY PAID ORDINARY SHARES
(3) 756,000 - FULLY PAID ORDINARY SHARES
(4) 30,000 - FULLY PAID ORDINARY SHARES
(5) 14,165,000 - FULLY PAID ORDINARY SHARES
(6) 90,000 - FULLY PAID ORDINARY SHARES
Nature of change
(1.1) N/A
(1.2) Option Expired
(2) N/A
(3) N/A
(4) N/A
(5) N/A
(6) N/A
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities
to which interest related
prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Part 3 - +Closed period
Were the interests in the securities or
contracts
detailed above traded during a
+closed period
where prior written clearance
was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
becomes ASX's property and may be made public.
Introduced 30/09/01
Amended 01/01/11
Name of entity
Alterity Therapeutics Limited
ABN
37 080 699 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for
the purposes of section 205G of the Corporations Act.
Name of director
Lawrence Gozlan
Date of last notice
24 April 2025
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
(1) Indirect - Montoya Pty Ltd <Buttercup A/C>
Nature of indirect interest
(including registered holder)
(1) Director
Date of change
(1.1) N/A
(1.2) 17 September 2025
(1.3) N/A
(1.4) N/A
No. of securities held prior to change
(1.1) 50,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(1.2) 7,000,000 - UNLISTED OPT EXP 17/09/2025
@ $0.09
(1.3) 4,545,455 - FULLY PAID ORDINARY
SHARES
(1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @
$0.028
Class
(1.1) UNLISTED OPT EXP 30/12/2027 @ $0.01
(1.2) UNLISTED OPT EXP 17/09/2025 @ $0.09
(1.3) FULLY PAID ORDINARY SHARES
(1.4) LISTED OPT EXP 26/02/2027 @ $0.028
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
Number acquired
(1.1) NIL
(1.2) NIL
(1.3) NIL
(1.4) NIL
Number disposed
(1.1) NIL
(1.2) (7,000,000 - UNLISTED OPT EXP 17/09/2025
@ $0.09)
(1.3) NIL
(1.4) NIL
Value/Consideration
(1.1) N/A
(1.2) NIL CONSIDERATION
(1.3) N/A
(1.4) N/A
No. of securities held after change
(1.1) 50,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(1.2) NIL - UNLISTED OPT EXP 17/09/2025 @
$0.09
(1.3) 4,545,455 - FULLY PAID ORDINARY
SHARES
(1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @
$0.028
Nature of change
(1.1) N/A
(1.2) Option Expired
(1.3) N/A
(1.4) N/A
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities
to which interest related
prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Part 3 - +Closed period
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director's Interest Notice
Were the interests in the securities or
contracts
detailed above traded during a
+closed period
where prior written clearance
was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
becomes ASX's property and may be made public.
Introduced 30/09/01
Amended 01/01/11
Name of entity
Alterity Therapeutics Limited
ABN
37 080 699 065
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for
the purposes of section 205G of the Corporations Act.
Name of director
Peter Marks
Date of last notice
24 April 2025
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
(1) Indirect - Lampam Pty Ltd
(2) Direct
(3) Indirect - Shanti Capital Pty Ltd <Peter Marks
Super Fund A/C>
Nature of indirect interest
(including registered holder)
(1) Director
(2) N/A
(3) SMSF
Date of change
(1.1) N/A
(1.2) N/A
(2.1) 17 September 2025
(2.2) N/A
(3.1) N/A
(3.2) N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
No. of securities held prior to change
(1.1) 7,185,968 - FULLY PAID ORDINARY
SHARES
(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @
$0.01
(2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025
@ $0.09
(2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(3.1) 1,818,182 - FULLY PAID ORDINARY
SHARES
(3.2) 606,061 - LISTED OPT EXP 26/02/2027 @
$0.028
Class
(1.1) FULLY PAID ORDINARY SHARES
(1.2) LISTED OPT EXP 31/08/2026 @ $0.01
(2.1) UNLISTED OPT EXP 17/09/2025 @ $0.09
(2.2) UNLISTED OPT EXP 30/12/2027 @ $0.01
(3.1) FULLY PAID ORDINARY SHARES
(3.2) LISTED OPT EXP 26/02/2027 @ $0.028
Number acquired
(1.1) NIL
(1.2) NIL
(2.1) NIL
(2.2) NIL
(3.1) NIL
(3.2) NIL
Number disposed
(1.1) NIL
(1.2) NIL
(2.1) (7,000,000 - UNLISTED OPT EXP 17/09/2025
@ $0.09)
(2.2) NIL
(3.1) NIL
(3.2) NIL
Value/Consideration
(1.1) N/A
(1.2) N/A
(2.1) NIL CONSIDERATION
(2.2) N/A
(3.1) N/A
(3.2) N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director's Interest Notice
No. of securities held after change
(1.1) 7,185,968 - FULLY PAID ORDINARY
SHARES
(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @
$0.01
(2.1) NIL - UNLISTED OPT EXP 17/09/2025 @
$0.09
(2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027
@ $0.01
(3.1) 1,818,182 - FULLY PAID ORDINARY
SHARES
(3.2) 606,061 - LISTED OPT EXP 26/02/2027 @
$0.028
Nature of change
(1.1) N/A
(1.2) N/A
(2.1) Options Expired
(2.2) N/A
(3.1) N/A
(3.2) N/A
Part 2 - Change of director's relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities
to which interest related
prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Part 3 - +Closed period
Were the interests in the securities or
contracts
detailed above traded during a
+closed period
where prior written clearance
was required?
No
If so, was prior written clearance provided to
allow the trade to proceed during this period?
N/A
If prior written clearance was provided, on
what date was this provided?
N/A
+
See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Share your feedback
Discover